ENZC (Enzolytics) Long-Term Debt: $0.02 Mil (As of Jun. 2011)


What is Enzolytics Long-Term Debt?

Enzolytics ENZC -12.50% Long-Term Debt is $0.02 Mil as of Jun. 2011.

Enzolytics's Long-Term Debt for the quarter that ended in Jun. 2011 was $0.02 Mil.

Enzolytics's quarterly Long-Term Debt declined from Dec. 2010 ($0.05 Mil) to Mar. 2011 ($0.02 Mil) but then stayed the same from Mar. 2011 ($0.02 Mil) to Jun. 2011 ($0.02 Mil).

Enzolytics's annual Long-Term Debt increased from Jul. 2008 ($0.00 Mil) to Dec. 2009 ($0.14 Mil) but then declined from Dec. 2009 ($0.14 Mil) to Dec. 2010 ($0.05 Mil).

Enzolytics  (OTCPK:ENZC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Enzolytics Long-Term Debt Related Terms

Enzolytics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Enzolytics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Long-Term Debt Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Long-Term Debt
0.29 0.00 0.14 0.05

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.29 0.05 0.02 0.02
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.02 Mil mean?
Enzolytics (ENZC) has a Long-Term Debt of $0.02 Mil as of Jun. 2011.
Is Enzolytics' Long-Term Debt too high?
Enzolytics' current Long-Term Debt is $0.02 Mil.
How does Enzolytics' Long-Term Debt compare to competitors?
Enzolytics' Long-Term Debt of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Enzolytics's current Long-Term Debt is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Long-Term Debt of $0.02 Mil. The current Long-Term Debt is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Enzolytics (ENZC), the current Long-Term Debt is $0.02 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.